(Q34767073)

4 August 2017

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features (English)

1 reference

4 August 2017

0 references

1 reference

2

C Szczylik

1 reference

4 August 2017

J Bellmunt

1

1 reference

4 August 2017

J Feingold

series ordinal

3

1 reference

4 August 2017

A Strahs

series ordinal

4

1 reference

4 August 2017

A Berkenblit

series ordinal

5

1 reference

4 August 2017

2 April 2008

1 reference

4 August 2017

1 reference

4 August 2017

19

1 reference

4 August 2017

1387-1392

1 reference

4 August 2017

8

1 reference

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

4 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Temsirolimus in the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Sirolimus--challenging current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Use of sirolimus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Sirolimus-associated proteinuria and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Impact on renal function of the use of sirolimus in cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN066

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN066

1 reference

4 August 2017

1 reference